Literature DB >> 7492487

A clinical trial of cyclosporine G in cadaveric renal transplantation.

M L Henry1, E A Elkhammas, E A Davies, R M Ferguson.   

Abstract

Cyclosporine G (OG 37-324) reportedly is an efficacious immunosuppressant with less nephrotoxicity than cyclosporine A. This is a prospective randomized double-blinded trial comparing cyclosporine G and cyclosporine A in cadaveric renal transplantation. Patient and graft survival, as well as major infectious complications, were not different between the two groups. Objective parameters of renal function, including serum creatinine, creatinine clearance, and inulin clearance, were routinely performed. These generally demonstrated less nephrotoxicity in those patients treated with cyclosporine G compared with cyclosporine A. Minor elevations of alanine aminotransferase were noted in the cyclosporine G-treated patients but this was not associated with acute morbidity. Overall, cyclosporine G appears to be equally as effective as cyclosporine A, but demonstrated notably less nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492487     DOI: 10.1007/bf00867684

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Nephrotoxicity of cyclosporine A and cyclosporine G in a rat model.

Authors:  A Tejani; I Lancman; A Pomrantz; M Khawar; C Chen
Journal:  Transplantation       Date:  1988-01       Impact factor: 4.939

2.  Sequential conventional immunotherapy with maintenance cyclosporine following renal transplantation.

Authors:  B G Sommer; M L Henry; R M Ferguson
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

3.  The efficacy and tolerability of cyclosporine G in human kidney transplant recipients.

Authors:  B Huser; G Thiel; M Oberholzer; T Beveridge; L Bianchi; M J Mihatsch; J Landmann
Journal:  Transplantation       Date:  1992-07       Impact factor: 4.939

4.  Cyclosporine A versus cyclosporine G: a comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice.

Authors:  M A Masri; M Naiem; S Pingle; A S Daar
Journal:  Transpl Int       Date:  1988-04       Impact factor: 3.782

5.  Beneficial effects of cyclosporine compared with azathioprine in cadaveric renal transplantation.

Authors:  M L Henry; B G Sommer; R M Ferguson
Journal:  Am J Surg       Date:  1985-11       Impact factor: 2.565

6.  A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.

Authors:  J S Najarian; D S Fryd; M Strand; D M Canafax; N L Ascher; W D Payne; R L Simmons; D E Sutherland
Journal:  Ann Surg       Date:  1985-02       Impact factor: 12.969

7.  A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years.

Authors: 
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

8.  In vivo fluorescence microscopy of kidney subcapsular blood flow in mice. Effects of cyclosporine, (NVA2)-cyclosporine, and isradipine, a new calcium antagonist.

Authors:  P Rooth; I Dawidson; N Clothier; K Diller
Journal:  Transplantation       Date:  1988-10       Impact factor: 4.939

  8 in total
  1 in total

Review 1.  Safety and efficacy of cyclosporine in the treatment of chronic dry eye.

Authors:  Clyde Schultz
Journal:  Ophthalmol Eye Dis       Date:  2014-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.